Axsome Healing Inc will certainly offer information on Sunosi (solriamfetol), consisting of arise from the SHARP research study, at the American Culture of Medical Psychopharmacology (ASCP) Yearly Fulfilling, being held from May 30 to June 3 in Miami.
According to the firm, Sunosi is showing renovation in cognitive feature in clients with too much daytime drowsiness related to obstructive rest apnea.
Information for the upcoming ASCP discussions are as adheres to:
Results of Solriamfetol on Cognitive Feature in Individuals with Cognitive Problems Related To Too Much Daytime Drowsiness in Obstructive Rest Apnea: Outcomes of the Sharp Research
Poster Session: Beauty Parlor 4
Lead Writer: Eileen Leary, PhD, Axsome Rehabs
Date/Time: Wednesday, Might 31, from 11:15 am– 1 pm ET
Too Much Daytime Drowsiness in a Real-World Research of Individuals with Obstructive Rest Apnea with or without Comorbid Anxiety
Poster Session: Beauty Parlor 4
Lead Writer: Samantha Floam, DMD, Axsome Rehabs
Date/Time: Thursday, June 1, from 12:30 pm– 2:15 pm ET
Preclinical Pharmacology of Solriamfetol: Prospective Devices for Wake Promo
Poster Session: Beauty Parlor 4
Lead Writer: Gregory Parks, PhD, Axsome Rehabs
Date/Time: Thursday, June 1, from 12:30 pm– 2:15 pm ET
Sunosi obtained United States Fda authorization on March 20, 2019, to boost wakefulness in grown-up clients with too much daytime drowsiness related to narcolepsy or obstructive rest apnea. Sunosi has orphan medicine classification for narcolepsy in the USA.
